Douglas Maffei | Senior Director-Investor Relations |
Daniel O'Day | Chairman and Chief Executive Officer |
Johanna Mercier | Chief Commercial Officer |
Christi Shaw | Chief Executive Officer-Kite |
Andrew Dickinson | Chief Financial Officer |
Merdad Parsey | Chief Medical Officer |
Diana Brainard | Senior Vice President and Head-HIV and Emerging Viruses Therapeutic |
Tyler Van Buren | Piper Sandler |
Geoffrey Porges | SVB Leerink |
Michael Yee | Jefferies |
Terence Flynn | Goldman Sachs |
Brian Abrahams | RBC Capital Market |
Geoff Meacham | Bank of America |
Evan Seigerman | Credit Suisse |
Matthew Harrison | Morgan Stanley |
Robyn Karnauskas | SunTrust |
Umer Raffat | Evercore ISI |
Alethia Young | Cantor Fitzgerald |
Ladies and gentlemen, thank you for standing by, and welcome to the Second Quarter 2020 Gilead Sciences Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your host today, Mr. Douglas Maffei, Senior Director of Investor Relations. Please go ahead.